0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Specific COX-2 Inhibitors Market Research Report 2026
Published Date: 2026-02-11
|
Report Code: QYRE-Auto-12X18041
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Specific COX 2 Inhibitors Market Research Report 2024
BUY CHAPTERS

Global Specific COX-2 Inhibitors Market Research Report 2026

Code: QYRE-Auto-12X18041
Report
2026-02-11
Pages:130
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Specific COX-2 Inhibitors Market

The global Specific COX-2 Inhibitors market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Specific COX-2 Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Specific COX-2 inhibitors are a class of medications that selectively inhibit the enzyme cyclooxygenase-2(COX-2),which is responsible for the production of prostaglandins involved in inflammation and pain response.By selectively blocking COX-2,these medications reduce inflammation and alleviate pain associated with conditions like arthritis,without significantly affecting COX-1-mediated functions in the stomach and kidneys.
The North American market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Specific COX-2 Inhibitors is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Specific COX-2 Inhibitors include Organon Pharma, Pfizer, Zentiva, Neopharmed Gentili, Eskayef Pharmaceuticals, Zydus, Teva, Mylan Pharmaceutical, Actavis, Jiangsu Hengrui Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Specific COX-2 Inhibitors market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Specific COX-2 Inhibitors. The Specific COX-2 Inhibitors market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Specific COX-2 Inhibitors market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Specific COX-2 Inhibitors manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Specific COX-2 Inhibitors Market Report

Report Metric Details
Report Name Specific COX-2 Inhibitors Market
Segment by Type
  • Etoricoxib
  • Imrecoxib
  • Celecoxib
  • Other
by Application
  • Osteoarthritis and Rheumatoid Arthritis
  • Dysmenorrhea
  • Relieve Acute Pain
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Organon Pharma, Pfizer, Zentiva, Neopharmed Gentili, Eskayef Pharmaceuticals, Zydus, Teva, Mylan Pharmaceutical, Actavis, Jiangsu Hengrui Pharmaceuticals, Qingdao Baheal Medical, Qilu Pharmaceutical, Shanxi Tongda Pharmaceutical, Sichuan Kelun Pharmaceutical, Jiangsu Chiatai Qingjiang Pharmaceutical, Beijing Yabao Biological Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Specific COX-2 Inhibitors manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Specific COX-2 Inhibitors sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Specific COX-2 Inhibitors Market report?

Ans: The main players in the Specific COX-2 Inhibitors Market are Organon Pharma, Pfizer, Zentiva, Neopharmed Gentili, Eskayef Pharmaceuticals, Zydus, Teva, Mylan Pharmaceutical, Actavis, Jiangsu Hengrui Pharmaceuticals, Qingdao Baheal Medical, Qilu Pharmaceutical, Shanxi Tongda Pharmaceutical, Sichuan Kelun Pharmaceutical, Jiangsu Chiatai Qingjiang Pharmaceutical, Beijing Yabao Biological Pharmaceutical

What are the Application segmentation covered in the Specific COX-2 Inhibitors Market report?

Ans: The Applications covered in the Specific COX-2 Inhibitors Market report are Osteoarthritis and Rheumatoid Arthritis, Dysmenorrhea, Relieve Acute Pain, Other

What are the Type segmentation covered in the Specific COX-2 Inhibitors Market report?

Ans: The Types covered in the Specific COX-2 Inhibitors Market report are Etoricoxib, Imrecoxib, Celecoxib, Other

1 Specific COX-2 Inhibitors Market Overview
1.1 Product Definition
1.2 Specific COX-2 Inhibitors by Type
1.2.1 Global Specific COX-2 Inhibitors Market Value by Type: 2025 vs 2032
1.2.2 Etoricoxib
1.2.3 Imrecoxib
1.2.4 Celecoxib
1.2.5 Other
1.3 Specific COX-2 Inhibitors by Application
1.3.1 Global Specific COX-2 Inhibitors Market Value by Application: 2025 vs 2032
1.3.2 Osteoarthritis and Rheumatoid Arthritis
1.3.3 Dysmenorrhea
1.3.4 Relieve Acute Pain
1.3.5 Other
1.4 Global Specific COX-2 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Specific COX-2 Inhibitors Revenue 2021–2032
1.4.2 Global Specific COX-2 Inhibitors Sales 2021–2032
1.4.3 Global Specific COX-2 Inhibitors Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Specific COX-2 Inhibitors Market Competition by Manufacturers
2.1 Global Specific COX-2 Inhibitors Sales Market Share by Manufacturers (2021–2026)
2.2 Global Specific COX-2 Inhibitors Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Specific COX-2 Inhibitors Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Specific COX-2 Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Specific COX-2 Inhibitors, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Specific COX-2 Inhibitors, Product Types and Applications
2.7 Global Key Manufacturers of Specific COX-2 Inhibitors, Date of Entry into the Industry
2.8 Global Specific COX-2 Inhibitors Market Competitive Situation and Trends
2.8.1 Global Specific COX-2 Inhibitors Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Specific COX-2 Inhibitors Players Market Share by Revenue
2.8.3 Global Specific COX-2 Inhibitors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Specific COX-2 Inhibitors Market Scenario by Region
3.1 Global Specific COX-2 Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Specific COX-2 Inhibitors Sales by Region: 2021–2032
3.2.1 Global Specific COX-2 Inhibitors Sales by Region: 2021–2026
3.2.2 Global Specific COX-2 Inhibitors Sales by Region: 2027–2032
3.3 Global Specific COX-2 Inhibitors Revenue by Region: 2021–2032
3.3.1 Global Specific COX-2 Inhibitors Revenue by Region: 2021–2026
3.3.2 Global Specific COX-2 Inhibitors Revenue by Region: 2027–2032
3.4 North America Specific COX-2 Inhibitors Market Facts & Figures by Country
3.4.1 North America Specific COX-2 Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Specific COX-2 Inhibitors Sales by Country (2021–2032)
3.4.3 North America Specific COX-2 Inhibitors Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Specific COX-2 Inhibitors Market Facts & Figures by Country
3.5.1 Europe Specific COX-2 Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Specific COX-2 Inhibitors Sales by Country (2021–2032)
3.5.3 Europe Specific COX-2 Inhibitors Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Specific COX-2 Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Specific COX-2 Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Specific COX-2 Inhibitors Sales by Region (2021–2032)
3.6.3 Asia Pacific Specific COX-2 Inhibitors Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Specific COX-2 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Specific COX-2 Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Specific COX-2 Inhibitors Sales by Country (2021–2032)
3.7.3 Latin America Specific COX-2 Inhibitors Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Specific COX-2 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Specific COX-2 Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2021–2032)
3.8.3 Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Specific COX-2 Inhibitors Sales by Type (2021–2032)
4.1.1 Global Specific COX-2 Inhibitors Sales by Type (2021–2026)
4.1.2 Global Specific COX-2 Inhibitors Sales by Type (2027–2032)
4.1.3 Global Specific COX-2 Inhibitors Sales Market Share by Type (2021–2032)
4.2 Global Specific COX-2 Inhibitors Revenue by Type (2021–2032)
4.2.1 Global Specific COX-2 Inhibitors Revenue by Type (2021–2026)
4.2.2 Global Specific COX-2 Inhibitors Revenue by Type (2027–2032)
4.2.3 Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021–2032)
4.3 Global Specific COX-2 Inhibitors Price by Type (2021–2032)
5 Segment by Application
5.1 Global Specific COX-2 Inhibitors Sales by Application (2021–2032)
5.1.1 Global Specific COX-2 Inhibitors Sales by Application (2021–2026)
5.1.2 Global Specific COX-2 Inhibitors Sales by Application (2027–2032)
5.1.3 Global Specific COX-2 Inhibitors Sales Market Share by Application (2021–2032)
5.2 Global Specific COX-2 Inhibitors Revenue by Application (2021–2032)
5.2.1 Global Specific COX-2 Inhibitors Revenue by Application (2021–2026)
5.2.2 Global Specific COX-2 Inhibitors Revenue by Application (2027–2032)
5.2.3 Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021–2032)
5.3 Global Specific COX-2 Inhibitors Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Organon Pharma
6.1.1 Organon Pharma Company Information
6.1.2 Organon Pharma Description and Business Overview
6.1.3 Organon Pharma Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Organon Pharma Specific COX-2 Inhibitors Product Portfolio
6.1.5 Organon Pharma Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Specific COX-2 Inhibitors Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Zentiva
6.3.1 Zentiva Company Information
6.3.2 Zentiva Description and Business Overview
6.3.3 Zentiva Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Zentiva Specific COX-2 Inhibitors Product Portfolio
6.3.5 Zentiva Recent Developments/Updates
6.4 Neopharmed Gentili
6.4.1 Neopharmed Gentili Company Information
6.4.2 Neopharmed Gentili Description and Business Overview
6.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
6.4.5 Neopharmed Gentili Recent Developments/Updates
6.5 Eskayef Pharmaceuticals
6.5.1 Eskayef Pharmaceuticals Company Information
6.5.2 Eskayef Pharmaceuticals Description and Business Overview
6.5.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
6.5.5 Eskayef Pharmaceuticals Recent Developments/Updates
6.6 Zydus
6.6.1 Zydus Company Information
6.6.2 Zydus Description and Business Overview
6.6.3 Zydus Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Zydus Specific COX-2 Inhibitors Product Portfolio
6.6.5 Zydus Recent Developments/Updates
6.7 Teva
6.7.1 Teva Company Information
6.7.2 Teva Description and Business Overview
6.7.3 Teva Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Teva Specific COX-2 Inhibitors Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Mylan Pharmaceutical
6.8.1 Mylan Pharmaceutical Company Information
6.8.2 Mylan Pharmaceutical Description and Business Overview
6.8.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.8.5 Mylan Pharmaceutical Recent Developments/Updates
6.9 Actavis
6.9.1 Actavis Company Information
6.9.2 Actavis Description and Business Overview
6.9.3 Actavis Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Actavis Specific COX-2 Inhibitors Product Portfolio
6.9.5 Actavis Recent Developments/Updates
6.10 Jiangsu Hengrui Pharmaceuticals
6.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.10.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.10.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
6.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.11 Qingdao Baheal Medical
6.11.1 Qingdao Baheal Medical Company Information
6.11.2 Qingdao Baheal Medical Description and Business Overview
6.11.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
6.11.5 Qingdao Baheal Medical Recent Developments/Updates
6.12 Qilu Pharmaceutical
6.12.1 Qilu Pharmaceutical Company Information
6.12.2 Qilu Pharmaceutical Description and Business Overview
6.12.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.12.5 Qilu Pharmaceutical Recent Developments/Updates
6.13 Shanxi Tongda Pharmaceutical
6.13.1 Shanxi Tongda Pharmaceutical Company Information
6.13.2 Shanxi Tongda Pharmaceutical Description and Business Overview
6.13.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.13.5 Shanxi Tongda Pharmaceutical Recent Developments/Updates
6.14 Sichuan Kelun Pharmaceutical
6.14.1 Sichuan Kelun Pharmaceutical Company Information
6.14.2 Sichuan Kelun Pharmaceutical Description and Business Overview
6.14.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.14.5 Sichuan Kelun Pharmaceutical Recent Developments/Updates
6.15 Jiangsu Chiatai Qingjiang Pharmaceutical
6.15.1 Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
6.15.2 Jiangsu Chiatai Qingjiang Pharmaceutical Description and Business Overview
6.15.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.15.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments/Updates
6.16 Beijing Yabao Biological Pharmaceutical
6.16.1 Beijing Yabao Biological Pharmaceutical Company Information
6.16.2 Beijing Yabao Biological Pharmaceutical Description and Business Overview
6.16.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.16.5 Beijing Yabao Biological Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Specific COX-2 Inhibitors Industry Chain Analysis
7.2 Specific COX-2 Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Specific COX-2 Inhibitors Production Mode & Process Analysis
7.4 Specific COX-2 Inhibitors Sales and Marketing
7.4.1 Specific COX-2 Inhibitors Sales Channels
7.4.2 Specific COX-2 Inhibitors Distributors
7.5 Specific COX-2 Inhibitors Customer Analysis
8 Specific COX-2 Inhibitors Market Dynamics
8.1 Specific COX-2 Inhibitors Industry Trends
8.2 Specific COX-2 Inhibitors Market Drivers
8.3 Specific COX-2 Inhibitors Market Challenges
8.4 Specific COX-2 Inhibitors Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Specific COX-2 Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Specific COX-2 Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Specific COX-2 Inhibitors Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Specific COX-2 Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Specific COX-2 Inhibitors Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Specific COX-2 Inhibitors Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Specific COX-2 Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Specific COX-2 Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Specific COX-2 Inhibitors, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Specific COX-2 Inhibitors, Product Types and Applications
 Table 12. Global Key Manufacturers of Specific COX-2 Inhibitors, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Specific COX-2 Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Specific COX-2 Inhibitors Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Specific COX-2 Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Specific COX-2 Inhibitors Sales by Region (K Units), 2021–2026
 Table 18. Global Specific COX-2 Inhibitors Sales Market Share by Region (2021–2026)
 Table 19. Global Specific COX-2 Inhibitors Sales by Region (K Units), 2027–2032
 Table 20. Global Specific COX-2 Inhibitors Sales Market Share by Region (2027–2032)
 Table 21. Global Specific COX-2 Inhibitors Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2021–2026)
 Table 23. Global Specific COX-2 Inhibitors Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2027–2032)
 Table 25. North America Specific COX-2 Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Specific COX-2 Inhibitors Sales by Country (K Units), 2021–2026
 Table 27. North America Specific COX-2 Inhibitors Sales by Country (K Units), 2027–2032
 Table 28. North America Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Specific COX-2 Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Specific COX-2 Inhibitors Sales by Country (K Units), 2021–2026
 Table 32. Europe Specific COX-2 Inhibitors Sales by Country (K Units), 2027–2032
 Table 33. Europe Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Specific COX-2 Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Specific COX-2 Inhibitors Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Specific COX-2 Inhibitors Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Specific COX-2 Inhibitors Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Specific COX-2 Inhibitors Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Specific COX-2 Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Specific COX-2 Inhibitors Sales by Country (K Units), 2021–2026
 Table 42. Latin America Specific COX-2 Inhibitors Sales by Country (K Units), 2027–2032
 Table 43. Latin America Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Specific COX-2 Inhibitors Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Specific COX-2 Inhibitors Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Specific COX-2 Inhibitors Sales (K Units) by Type (2021–2026)
 Table 51. Global Specific COX-2 Inhibitors Sales (K Units) by Type (2027–2032)
 Table 52. Global Specific COX-2 Inhibitors Sales Market Share by Type (2021–2026)
 Table 53. Global Specific COX-2 Inhibitors Sales Market Share by Type (2027–2032)
 Table 54. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021–2026)
 Table 57. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2027–2032)
 Table 58. Global Specific COX-2 Inhibitors Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Specific COX-2 Inhibitors Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Specific COX-2 Inhibitors Sales (K Units) by Application (2021–2026)
 Table 61. Global Specific COX-2 Inhibitors Sales (K Units) by Application (2027–2032)
 Table 62. Global Specific COX-2 Inhibitors Sales Market Share by Application (2021–2026)
 Table 63. Global Specific COX-2 Inhibitors Sales Market Share by Application (2027–2032)
 Table 64. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021–2026)
 Table 67. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2027–2032)
 Table 68. Global Specific COX-2 Inhibitors Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Specific COX-2 Inhibitors Price (US$/Unit) by Application (2027–2032)
 Table 70. Organon Pharma Company Information
 Table 71. Organon Pharma Description and Business Overview
 Table 72. Organon Pharma Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Organon Pharma Specific COX-2 Inhibitors Product
 Table 74. Organon Pharma Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Pfizer Specific COX-2 Inhibitors Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. Zentiva Company Information
 Table 81. Zentiva Description and Business Overview
 Table 82. Zentiva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Zentiva Specific COX-2 Inhibitors Product
 Table 84. Zentiva Recent Developments/Updates
 Table 85. Neopharmed Gentili Company Information
 Table 86. Neopharmed Gentili Description and Business Overview
 Table 87. Neopharmed Gentili Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Neopharmed Gentili Specific COX-2 Inhibitors Product
 Table 89. Neopharmed Gentili Recent Developments/Updates
 Table 90. Eskayef Pharmaceuticals Company Information
 Table 91. Eskayef Pharmaceuticals Description and Business Overview
 Table 92. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product
 Table 94. Eskayef Pharmaceuticals Recent Developments/Updates
 Table 95. Zydus Company Information
 Table 96. Zydus Description and Business Overview
 Table 97. Zydus Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Zydus Specific COX-2 Inhibitors Product
 Table 99. Zydus Recent Developments/Updates
 Table 100. Teva Company Information
 Table 101. Teva Description and Business Overview
 Table 102. Teva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Teva Specific COX-2 Inhibitors Product
 Table 104. Teva Recent Developments/Updates
 Table 105. Mylan Pharmaceutical Company Information
 Table 106. Mylan Pharmaceutical Description and Business Overview
 Table 107. Mylan Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Mylan Pharmaceutical Specific COX-2 Inhibitors Product
 Table 109. Mylan Pharmaceutical Recent Developments/Updates
 Table 110. Actavis Company Information
 Table 111. Actavis Description and Business Overview
 Table 112. Actavis Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Actavis Specific COX-2 Inhibitors Product
 Table 114. Actavis Recent Developments/Updates
 Table 115. Jiangsu Hengrui Pharmaceuticals Company Information
 Table 116. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
 Table 117. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product
 Table 119. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
 Table 120. Qingdao Baheal Medical Company Information
 Table 121. Qingdao Baheal Medical Description and Business Overview
 Table 122. Qingdao Baheal Medical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. Qingdao Baheal Medical Specific COX-2 Inhibitors Product
 Table 124. Qingdao Baheal Medical Recent Developments/Updates
 Table 125. Qilu Pharmaceutical Company Information
 Table 126. Qilu Pharmaceutical Description and Business Overview
 Table 127. Qilu Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 128. Qilu Pharmaceutical Specific COX-2 Inhibitors Product
 Table 129. Qilu Pharmaceutical Recent Developments/Updates
 Table 130. Shanxi Tongda Pharmaceutical Company Information
 Table 131. Shanxi Tongda Pharmaceutical Description and Business Overview
 Table 132. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 133. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product
 Table 134. Shanxi Tongda Pharmaceutical Recent Developments/Updates
 Table 135. Sichuan Kelun Pharmaceutical Company Information
 Table 136. Sichuan Kelun Pharmaceutical Description and Business Overview
 Table 137. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 138. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product
 Table 139. Sichuan Kelun Pharmaceutical Recent Developments/Updates
 Table 140. Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
 Table 141. Jiangsu Chiatai Qingjiang Pharmaceutical Description and Business Overview
 Table 142. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 143. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product
 Table 144. Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments/Updates
 Table 145. Beijing Yabao Biological Pharmaceutical Company Information
 Table 146. Beijing Yabao Biological Pharmaceutical Description and Business Overview
 Table 147. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 148. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product
 Table 149. Beijing Yabao Biological Pharmaceutical Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Specific COX-2 Inhibitors Distributors List
 Table 153. Specific COX-2 Inhibitors Customers List
 Table 154. Specific COX-2 Inhibitors Market Trends
 Table 155. Specific COX-2 Inhibitors Market Drivers
 Table 156. Specific COX-2 Inhibitors Market Challenges
 Table 157. Specific COX-2 Inhibitors Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Specific COX-2 Inhibitors
 Figure 2. Global Specific COX-2 Inhibitors Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Specific COX-2 Inhibitors Market Share by Type: 2025 & 2032
 Figure 4. Etoricoxib Product Picture
 Figure 5. Imrecoxib Product Picture
 Figure 6. Celecoxib Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global Specific COX-2 Inhibitors Market Value by Application (US$ Million), 2021–2032
 Figure 9. Global Specific COX-2 Inhibitors Market Share by Application: 2025 & 2032
 Figure 10. Osteoarthritis and Rheumatoid Arthritis
 Figure 11. Dysmenorrhea
 Figure 12. Relieve Acute Pain
 Figure 13. Other
 Figure 14. Global Specific COX-2 Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Specific COX-2 Inhibitors Market Size (US$ Million), 2021–2032
 Figure 16. Global Specific COX-2 Inhibitors Sales (K Units), 2021–2032
 Figure 17. Global Specific COX-2 Inhibitors Average Price (US$/Unit), 2021–2032
 Figure 18. Specific COX-2 Inhibitors Report Years Considered
 Figure 19. Specific COX-2 Inhibitors Sales Share by Manufacturers in 2025
 Figure 20. Global Specific COX-2 Inhibitors Revenue Share by Manufacturers in 2025
 Figure 21. Top 5 and Top 10 Global Specific COX-2 Inhibitors Players: Market Share by Revenue in Specific COX-2 Inhibitors in 2025
 Figure 22. Specific COX-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 23. Global Specific COX-2 Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 24. North America Specific COX-2 Inhibitors Sales Market Share by Country (2021–2032)
 Figure 25. North America Specific COX-2 Inhibitors Revenue Market Share by Country (2021–2032)
 Figure 26. United States Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. Canada Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. Europe Specific COX-2 Inhibitors Sales Market Share by Country (2021–2032)
 Figure 29. Europe Specific COX-2 Inhibitors Revenue Market Share by Country (2021–2032)
 Figure 30. Germany Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. France Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. U.K. Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Italy Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Russia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Asia Pacific Specific COX-2 Inhibitors Sales Market Share by Region (2021–2032)
 Figure 36. Asia Pacific Specific COX-2 Inhibitors Revenue Market Share by Region (2021–2032)
 Figure 37. China Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Japan Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. South Korea Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. India Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Australia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. China Taiwan Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Southeast Asia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Latin America Specific COX-2 Inhibitors Sales Market Share by Country (2021–2032)
 Figure 45. Latin America Specific COX-2 Inhibitors Revenue Market Share by Country (2021–2032)
 Figure 46. Mexico Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Brazil Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Argentina Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Colombia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share by Country (2021–2032)
 Figure 51. Middle East and Africa Specific COX-2 Inhibitors Revenue Market Share by Country (2021–2032)
 Figure 52. Turkey Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Saudi Arabia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. UAE Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Global Sales Market Share of Specific COX-2 Inhibitors by Type (2021–2032)
 Figure 56. Global Revenue Market Share of Specific COX-2 Inhibitors by Type (2021–2032)
 Figure 57. Global Specific COX-2 Inhibitors Price (US$/Unit) by Type (2021–2032)
 Figure 58. Global Sales Market Share of Specific COX-2 Inhibitors by Application (2021–2032)
 Figure 59. Global Revenue Market Share of Specific COX-2 Inhibitors by Application (2021–2032)
 Figure 60. Global Specific COX-2 Inhibitors Price (US$/Unit) by Application (2021–2032)
 Figure 61. Specific COX-2 Inhibitors Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network